Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siRNA (PTP4A3)
- Development stage
- Preclinical
- Lead developer
- The First Affiliated Hospital, Anhui Medical University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
siRNA (PTP4A3) is a small interfering RNA therapeutic candidate designed to silence the expression of Protein Tyrosine Phosphatase 4A3 (PTP4A3), also known as PRL-3. PTP4A3 is a member of the protein tyrosine phosphatase family that is aberrantly overexpressed in various malignancies, including acute myeloid leukemia (AML), and is associated with poor prognosis. By mediating the degradation of PTP4A3 mRNA, this siRNA inhibits the activation of the AKT/mTOR signaling pathway, which is critical for leukemia cell survival and proliferation. Preclinical studies conducted by researchers at the First Affiliated Hospital of Anhui Medical University have shown that PTP4A3 knockdown reduces cell growth and induces apoptosis in AML cell lines and slows tumor growth in vivo.
- Other names
- PTP4A3 siRNAPTP-4A3 siRNAPTP 4A3 siRNAsi-PTP4A3si-PTP-4A3si-PTP 4A3
02
Targets
PTP4A3 (Phosphatase of regenerating liver 3)
Beyond the preview
Go deeper on siRNA (PTP4A3).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siRNA (PTP4A3).